Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS

NCT01970865 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01970865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
January 8, 2014
Completion date
May 24, 2023
Enrollment
364 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non small cell lung cancer (nsclc) and ros1-positive nsclc